Synergy Vision MD appointed as trustee of the Cystic Fibrosis Trust
June 17, 2016Medical Communications Synergy Vision, appointment, cystic fibrosis, cystic fibrosis trust, medical communications, medical communications agency
Managing director of Synergy Vision Ffyona Dawber has been appointed to the Cystic Fibrosis Trust’s board of trustees. Her wealth …
Nice backs BMS’ combination immunotherapy Opdivo, Yervoy to treat skin cancer
June 17, 2016Medical Communications, Research and Development, Sales and Marketing BMS, NICE, oncology, opdivo, regulation, skin cancer
The National Institute for Health and Care Excellence (Nice) has backed a combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and …
Pfizer breaks ground on new $200 million biologics facility
June 17, 2016Medical Communications, Research and Development Manufacturing Facility, Pfizer
Pfizer (NYSE: PFE) has broken ground on a new $200 million biologics clinical manufacturing facility in Andover, Massachusetts. This expansion …
WellBe bracelet, mobile app to help manage stress
June 17, 2016Medical Communications, Research and Development HealthTech, WellBe, app, stress, wearable technology
Adding to the growing list of healthcare applications, a new technology claims to have created the first anti-stress biofeedback bracelet …
Merck & Co says Keytruda shows better results than chemotherapy in Phase III trials for lung cancer
June 17, 2016Medical Communications MSD, Merck & Co, drug trial, keytruda, lung cancer
US drug major Merck & Co (NYSE: MRK) said late-stage trials for its immunotherapy Keytruda (pembrolizumab) to treat advanced non-small-cell …
Final Nice appraisal says no to cystic fibrosis drug, Orkambi
June 17, 2016Medical Communications NICE, Orkambi, Vertex Pharma, cystic fibrosis, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) has issued a final appraisal determination rejecting cystic fibrosis drug, Orkambi …
Roche gets a NICE knockback for melanoma drug, Cotellic
June 16, 2016Medical Communications, Research and Development, Sales and Marketing Cotellic, NICE, Roche
The National Institute for Health and Care Excellence (NICE) has announced that that it has not recommended Roche’s melanoma drug, …
SMC recommends treatment for potentially fatal chemotherapy-related disease
June 16, 2016Research and Development, Sales and Marketing Menarini, SMC, adneuric
The Scottish Medicines Consortium has recommended Adenuric (febuxostat), a treatment for a severe complication that can affect chemotherapy patients in …
Chiasma cuts staff by 33% after FDA rejects rare disease drug, Mycapssa
June 16, 2016Research and Development, Sales and Marketing FDA, chiasma, cutbacks, failure, workforce cuts
US-based biopharmaceutical company, Chiasma (NASDAQ: CHMA), has announced substantial job cuts as it attempts to restructure following the US Food …
UK biotech in great shape, according to new industry report
June 16, 2016Research and Development Europe, UK, biotech, uk bioindustry association
The UK biotechnology sector is going from strength to strength, having raised an “unprecedented” £900 million on the London Stock …
Roche secures EU approval for Gazyvaro in new lymphoma indication
June 16, 2016Research and Development, Sales and Marketing EU, Gazyvaro, Roche, follicular lymphoma
Roche (SIX: RO) has announced that the European Commission has approved Gazyvaro (obinutuzumab), in combination with bendamustine chemotherapy, in patients …
Teva returns rights to heart cell therapy to Mesoblast
June 16, 2016Research and Development, Sales and Marketing Mesoblast, Teva, chronic heart failure, phase III
Israeli drugmaker Teva (NYSE: TEVA) has returned full rights to a drug for heart condition in late stage trials to …
Marathon Pharma submits application for Duchenne muscular dystrophy drug to FDA
June 15, 2016Research and Development, Sales and Marketing FDA, duchenne, marathon pharmaceuticals
Marathon Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …
Phase II failure sees stock plunge and job cutbacks for Infinity Pharmaceuticals
June 15, 2016Research and Development, Sales and Marketing AbbVie, infinity pharmaceuticals, non-Hodgkin lymphoma, trial failure
Shares at Infinity Pharmaceuticals (NASDAQ: INFI) fell around 70% upon the announcement of new Phase II data for their non-Hodgkin …
Sobi says US FDA approves higher dose of Orfadin to treat rare genetic disorder
June 15, 2016Research and Development, Sales and Marketing US FDA, genetic disorder, regulation, sobi
Swedish Orphan Biovitrum AB (Sobi) on Wednesday said the US Food and Drug Administration (FDA) has approved a higher strength …
FDA issues warnings on Janssen, AstraZeneca diabetes drugs
June 15, 2016Research and Development, Sales and Marketing AstraZeneca, FDA, Janssen, farxiga, invokana
The US Food and Drug Administration has issued a warning of the risk of acute kidney injury for the type-2 …
German Supreme Court grants Lilly appeal to block Alimta generics
June 15, 2016Research and Development, Sales and Marketing Actavis, Alimta, Eli Lilly
Eli Lilly (NYSE: LLY) has announced that it has been granted an appeal by the German Federal Supreme Court, in …
Actelion says blood pressure drug Uptravi now available in Germany
June 15, 2016Research and Development, Sales and Marketing Actelion, EU, blood pressure, product launch
Actelion (SIX: ATLN) said its high blood pressure drug Uptravi (selexipag) is now available in Germany. The European Commission granted …
Novartis says to develop antimalarial treatment with Medicines for Malaria Venture
June 15, 2016Research and Development, Sales and Marketing Novartis, antimalarial drug, drug trial
Swiss pharma major Novartis (NYSE: NVS) said it has partnered with Medicines for Malaria Venture (MMV) and the Bill & Melinda …
Shire adds to gastrointestinal portfolio with Pfizer compound acquisition
June 14, 2016Research and Development, Sales and Marketing Pfizer, Shire, acquisition, compound
Shire (LSE: SHP) has announced that it has acquired an investigational biologic for the treatment inflammatory bowel disease from Pfizer …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
